Verastem Inc VSTM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VSTM is a good fit for your portfolio.
News
-
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
-
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
-
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
-
Verastem Oncology's Ovarian Cancer Drug Gets FDA Orphan Drug Designation
-
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
-
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
Trading Information
- Previous Close Price
- $9.69
- Day Range
- $9.77–9.92
- 52-Week Range
- $4.27–15.18
- Bid/Ask
- $9.75 / $9.78
- Market Cap
- $247.26 Mil
- Volume/Avg
- 21,129 / 149,198
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 73
- Website
- https://www.verastem.com
Comparables
Valuation
|
Metric
|
VSTM
|
BLUE
|
FDMT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.29 | 0.49 | 3.69 |
Price/Sales | — | 4.77 | 49.83 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VSTM
|
BLUE
|
FDMT
|
|---|---|---|---|
Quick Ratio | 5.20 | 1.24 | 15.21 |
Current Ratio | 5.45 | 1.55 | 15.65 |
Interest Coverage | −21.61 | — | — |
Quick Ratio
VSTM
BLUE
FDMT
Profitability
|
Metric
|
VSTM
|
BLUE
|
FDMT
|
|---|---|---|---|
Return on Assets (Normalized) | −55.56% | −12.29% | −25.94% |
Return on Equity (Normalized) | −126.34% | −30.63% | −28.64% |
Return on Invested Capital (Normalized) | −71.79% | −15.27% | −31.25% |
Return on Assets
VSTM
BLUE
FDMT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bxxbdxnky | Ddd | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nypzflqj | Ykxydf | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pwjbktwlg | Rnmkt | $98.8 Bil | |
MRNA
| Moderna Inc | Wlwdntmf | Kspkw | $38.8 Bil | |
ARGX
| argenx SE ADR | Lpdyywfpg | Bbzm | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Cqbklbwl | Kgxr | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mzmvbfjb | Njrtvwv | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gnsswvt | Blmbbr | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fmmzkzydv | Grvdyls | $12.4 Bil | |
INCY
| Incyte Corp | Qfztgbf | Qpzbmb | $11.9 Bil |